Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. In this regard, the company has attached a press release.
The above information is a part of company’s filings submitted to BSE.